Replacement of obsolete, legacy and business critical test methods for QC release of a medical ultrasound device

“Deltex很高兴地宣布，通过成功竞标创新者分析第3轮：迷你项目第二阶段的竞争，公司获得了Innovate UK的资助。“创新英国”基金为英国提供了与世界一流机构合作的机会，以寻求改进现有技术的解决方案。Deltex Medical很高兴能与美国国家物理实验室（NPL）合作开展一个项目，以提高其血流动力学监测探头的质量控制。Deltex是全球领先的多普勒超声血流动力学监测。使用该公司的TrueVue多普勒已被证明可以减少术后并发症，并被NICE推荐。该系统还为医院节省了治疗并发症的费用，否则会导致住院时间的延长。微创TrueVue多普勒技术将超声探头插入患者的食道（食物管道）。食道靠近患者胸部的主动脉，因此可以测量血流速度，就像警察的测速摄像机检查汽车的速度一样。在这种情况下，移动的物体是血细胞。TrueVue系统测量血液流速和每次心跳的时间。然后，TrueVue计算一系列对临床医生管理患者护理有用的参数，以尽量减少甚至预防术后并发症。Deltex将利用这笔资金与国家物理实验室合作进行一项研究，以进一步提高探测器超声输出的质量控制测量。与国家物理实验室合作将带来相当多的超声专业知识和专业设备。这将更好地理解超声晶体的能量图，并提供创新的方法来创建新一代的产品测试设备。设想的系统还将以数字方式存储所有结果，以便进行快速趋势分析。结果将是，产品质量的提高将为NICE推荐的设备提供更多的使用，以减少术后并发症，住院时间（3天）和医疗费用（每位患者1,100英镑）。总之，一个成功的项目将通过加强质量管理使临床医生和患者都受益。Deltex预计，这一结果将扩大已经证明有效的医疗设备的使用范围。”

"Deltex are pleased to announce that it has gained Innovate UK funding through a successful bid to the Analysis for innovators round 3: mini projects phase 2 competition. This Innovate UK funding brings with it the opportunity to collaborate with world-class UK agencies to seek solutions to improve existing technologies. Deltex Medical is pleased to be partnering with the National Physics Laboratory (NPL) in a project to enhance the Quality Control of its haemodynamic monitoring probes.Deltex is the world leader in Doppler ultrasound for haemodynamic monitoring. Use of the company's TrueVue Doppler, is proven to reduce post-operative complications and is recommended by NICE. The system also saves hospitals the costs of treating complications that would otherwise result in increased lengths of stay.The minimally invasive TrueVue Doppler technology uses an ultrasound probe inserted into the patient's oesophagus (food pipe). The oesophagus lies close to the aorta in the patient's chest and so blood flow velocity can be measured much like a police speed camera checks a car's speed. In this case the moving objects are blood cells.The TrueVue system measures blood flow velocity and the timing of each heartbeat. TrueVue then calculates a range of parameters useful to clinicians in managing patient care to minimise or even prevent post-operative complications.Deltex will use the grant monies to collaborate with NPL in a study to further enhance the Quality Control measurements of the probe's ultrasound output. Partnering with NPL will bring considerable ultrasound expertise and access to specialised equipment. This will provide a better understanding of the energy map of the ultrasound crystals and deliver innovative methods to create a new generation of product test equipment. The system envisaged will also store all results digitally allowing rapid trend analyses. The result will be that the product's enhanced quality will provide increased use of a device already recommended by NICE to reduce post-operative complications, hospital stay (-3 days) and healthcare costs (£1,100 per patient).In conclusion a successful project will benefit clinicians and patients alike through enhanced quality management. Deltex expects that the outcome will increase the range of uses of a medical device with already proven efficacy."